Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eslicarbazepine acetate for prevention of post-stroke epilepsy in high-risk patients
MOH_2019-06-11_007196Phase 2Completed
- Sponsor
- BIAL
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epilepsy comparing Eslicarbazepine acetate with Matching placebo (2 arms). Primary endpoint: Occurrence of unprovoked seizures within 6 months. Started Apr 2019; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on MOH_2019-06-11_007196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-11_007196.